Not Applicable
Not Applicable
A stent is a medical device introduced to a body lumen and is well known in the art. Typically, a stent is implanted in a blood vessel at the site of a stenosis or aneurysm endoluminally, i.e. by so-called “minimally invasive techniques” in which the stent in a radially reduced configuration, optionally restrained in a radially compressed configuration by a sheath and/or catheter, is delivered by a stent delivery system or “introducer” to the site where it is required. The introducer may enter the body from an access location outside the body, such as through the patient's skin, or by a “cut down” technique in which the entry blood vessel is exposed by minor surgical means.
Stents, grafts, stent-grafts, vena cava filters, expandable frameworks, and similar implantable medical devices are radially expandable endoprostheses which are typically intravascular implants capable of being implanted transluminally and enlarged radially after being introduced percutaneously. Stents may be implanted in a variety of body lumens or vessels such as within the vascular system, urinary tracts, bile ducts, fallopian tubes, coronary vessels, secondary vessels, etc. They may be self-expanding, expanded by an internal radial force, such as when mounted on a balloon, or a combination of self-expanding and balloon expandable (hybrid expandable).
Stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids.
Within the vasculature, it is not uncommon for stenoses to form at a vessel bifurcation. A bifurcation is an area of the vasculature or other portion of the body where a first (or parent) vessel is bifurcated into two or more branch vessels. Where a stenotic lesion or lesions form at such a bifurcation, the lesion(s) can affect only one of the vessels (i.e., either of the branch vessels or the parent vessel) two of the vessels, or all three vessels. Many prior art stents however are not wholly satisfactory for use where the site of desired application of the stent is juxtaposed or extends across a bifurcation in an artery or vein such, for example, as the bifurcation in the mammalian aortic artery into the common iliac arteries.
The art referred to and/or described above is not intended to constitute an admission that any patent, publication or other information referred to herein is “prior art” with respect to this invention. In addition, this section should not be construed to mean that a search has been made or that no other pertinent information as defined in 37 C.F.R. §1.56(a) exists.
All US patents and applications and all other published documents mentioned anywhere in this application are incorporated herein by reference in their entirety.
Without limiting the scope of the invention a brief summary of some of the claimed embodiments of the invention is set forth below. Additional details of the summarized embodiments of the invention and/or additional embodiments of the invention may be found in the Detailed Description of the Invention below.
In at least one embodiment, the invention is directed to a stent with a side branch comprising a plurality of members defining at least one cell having at least two stable cell geometries, a “bi-stable” cell. In some embodiments, some of the plurality of members of the stent form a double bi-stable cell geometry. In other embodiments, at least one of the members defining the bi-stable cell has at least one hinge. In some embodiments, the side branch has a plurality of cells having at least two stable cell geometries arranged in a column.
These and other embodiments which characterize the invention are pointed out with particularity in the claims annexed hereto and forming a part hereof. However, for further understanding of the invention, its advantages and objectives obtained by its use, reference can be made to the drawings which form a further part hereof and the accompanying descriptive matter, in which there is illustrated and described an embodiments of the invention.
A detailed description of the invention is hereafter described with specific reference being made to the drawings.
While this invention may be embodied in many different forms, there are described in detail herein specific embodiments of the invention. This description is an exemplification of the principles of the invention and is not intended to limit the invention to the particular embodiments illustrated.
For the purposes of this disclosure, like reference numerals in the figures shall refer to like features unless otherwise indicated.
As used herein the term ‘stent’ refers to an expandable prosthesis for implantation into a body lumen or vessel and includes devices such as stents, grafts, stent-grafts, vena cava filters, expandable frameworks, etc.
As used herein, the term ‘bi-stable cell’ refers to a cell that has two or more discrete stable configurations, geometries and/or states 36,38. Thus, bi-stable cells includes cells that are multi-stable, i.e. cells with more than two discrete stable configurations.
Referring now to the drawings which are for the purposes of illustrating embodiments of the invention only and not for purposes of limiting same,
When a force is applied to the bi-stable cell 48, the bi-stable cell 48 will tend to, or exert a force in the direction of, one of the discrete configurations. In at least one embodiment, the bi-stable cell 48 will tend to one or another of the first and second configurations 36, 38 depending on whether the bi-stable cell 48 has been compressed beyond a transition point. If the bi-stable cell 48 has been compressed beyond the transition point, the bi-stable cell 48 will tend toward a closed configuration, or first state 36. Conversely, if the bi-stable cell 48 has not been compressed to the transition point, the bi-stable cell 48 will tend towards an open configuration or second state 38. As expansive forces are applied to the side branch 20 of the stent 10, the first cell segment 32 and the second cell segments 34 will move away from one another so that the bi-stable cell 48 widens and expands, thereby increasing the area of the bi-stable cell 48.
Thus, the bi-stable cell 48 has an equilibrium position between two stable states, e.g. the first and second states 36, 38. When the force applied to the bi-stable cell 48 exceeds the equilibrium position, the bi-stable cell 48 snaps into one of its stable states depending upon the original state of the bi-stable cell 48 and the direction of the force. Note, that in a bi-stable cell 48, all positions between the stable states, e.g. the first and second states 36, 38, are unstable and can only be maintained by an external force. In a bi-stable cell 48 with more than two stable states, there is an equilibrium position between each stable state. For example, in a bi-stable cell 48 with a first state 36, an intermediate state 37 and a second state 38 there is an equilibrium position between the first state 36 and the intermediate state 37 and an equilibrium position between the intermediate state 37 and the second state 38. Bi-stable cells are also discussed in commonly assigned application Ser. No. 11/368,913, entitled Non-Foreshortening Sheaths and Assemblies for Use, hereby incorporated by reference in its entirety.
As shown, for example in
Note that the first and second cell segments 32, 34 can have any length. The length and/or the configuration of the first and second cell segments 32, 34 affects the area of the bi-stable cell 48 in both the first and second states 36, 38. The bi-stable cell 48 has a first area (A1) in the first state 36, a second area (A2) in the second state 38 and the first area (A1) is smaller than the second area (A2).
Each cell segment 32, 34 has a length. If the cell segment 32, 34 is not straight, the length is the pathway from one end of the cell segment 32, 34 to the second end of the cell segment 32, 34. As shown in
In some embodiments, the first and second cell segments 32, 34 have the same configuration in the first state 36 and in the second state 38, as shown, for example, in
In other embodiments, the first and second cell segments 32, 34 have the same configuration in the first state 36 and different configurations in the second state 38, as shown, for example, in
In some embodiments, the first and second cell segments 32, 34 have different configurations in both the first and second states 36, 38. For example, as shown in
The shape of the first and second cell segments 32, 34 and the relationship of the first and second cell segments 32, 34 to one another determines the configuration or cell geometry of the bi-stable cell 48. As shown in the figures, the cell geometry of the bi-stable cell 48 is different in the first and second states 36, 38. Thus, the bi-stable cell 48 has a first stable cell geometry in the first state 36 and a second stable cell geometry in the second state 38 and the first and second stable cell geometries are different from one another.
For example, in
Other examples of different stable cell geometries in the first and second states 36, 38 are shown in
In at least one embodiment, shown for example, in
In at least one embodiment, a bi-stable cell 48 defined by at least one cell segment 32, 34 having hinges 40 has more than two stable states, 36, 37, 38. For example, the bi-stable cell 48 shown in
Thus, in this embodiment, the bi-stable cell 48 has more than two stable cell geometries. The bi-stable cell 48 has a first state 36 cell geometry, two different intermediate state cell geometry embodiments 37a,b and a second state cell geometry 38. Similar to
In at least one embodiment, members of the stent 10 are arranged to form a double bi-stable cell, as shown, for example, in
In some embodiments, the first cell 48a and the second cell 48b have the same configuration in both the first state 36 and the second state 38. In other embodiments, the first cell 48a and the second cell 48b have the same configuration in the first state 36 and different configurations in the second state 38. One example of this embodiment, is if the first cell 48a has a configuration like
In at least one embodiment, a connector 44 is engaged to the first cell segment 32 and/or the second cell segment 34. In at least one embodiment, the connectors 44 aid in the transition of the bi-stable cell from the first state 36 to the second state 38. In some embodiments, the connectors 44 open the bi-stable geometry by a twisting motion. In other embodiments, the connectors 44 open the bi-stable geometry due to the tension the connectors 44 exert on the second cell segment 34. In some embodiments, both second cell segments 34a,b of a double bi-stable cell transition to the second state 38. In other embodiments, only one of the second cell segments of a double bi-stable cell transitions to the second state 38.
In
In some embodiments, bi-stable cells 48 are engaged to one another to form of columns 50 of bi-stable cells 48, as shown, for example, in
In some embodiments, adjacent bi-stable cells 48 are directly engaged, as shown in
In other embodiments, adjacent bi-stable cells 48 in a column 50 of bi-stable cells 48 are engaged by a connector 44, for example as shown in
Because any suitable stent geometry may be used for the tubular body of the stent 10, many figures only show the side branch 20 of the stent 10 without any structure, or only a small portion of structure, shown for the rest of the tubular body of the stent 10. It is understood that any suitable structure may be employed for the tubular body of the stent 10 including, but not limited to, the cellular patterns, shown by way of example only, in
One skilled in the art will recognize that the bi-stable cell geometries shown in
It is also within the scope of the invention for the side branch 20 to have bi-stable cells 48 which define different areas in the first state 36 and/or different area in the second state 38. For example, the side branch 20 in
The side branch 20 in
As shown in
A long member 24 is engaged to the perimeter member 22. In some embodiments one end of the long member 24 is directly engaged to the perimeter member 22, as shown in
The side branch 20 further comprises a first cell segment 32 and a second cell segment 34, which are engaged to the long member 24. As discussed above, the first and second cell segments 32, 34 define a bi-stable cell 48. In some embodiments, the segments 32, 34 are directly engaged to the long member 24 by a portion of the first cell segment 32, as shown, for example, in
As shown in
In at least one embodiment, the second cell segment 34 is engaged to the adjacent long member 24. As shown in
The side branch 20 also has at least one petal 46. As shown in
It is within the scope of the invention for the petal 46 to have more than one bi-stable cell 48. For example, as shown in
In the side branch 20 configuration of
The bi-stable cells 48 in columns 50 have the same configuration in
In some embodiments, the columns 50 are non-tapered. In other embodiments, the columns 50 are tapered, as shown, for example, in
In at least one embodiment, the bi-stable cells 48 of the side branch 20 are arranged so that the side branch 20 extends farther into the side branch vessel when the side branch 20 is in an expanded state. For example, the bi-stable cells 48 are oriented so that the when the bi-stable cell 48 transitions to the second stable state 38, the second cell segment 34 assumes a position that is farther away from the tubular body of the stent. As shown in
In at least one embodiment, the orientation of the bi-stable cells 48 affects the diameter of the side branch 20. In some embodiments, the side branch 20 comprises at least one ring 52 of bi-stable cells 48. In this embodiment, the bi-stable cells 48 extend about the circumference of the side branch 20.
In some embodiments, bi-stable cells 48 of adjacent rings 52 can be engaged either to a bi-stable cell 48b in the adjacent ring 52 by a connector 44c or to a connector 44a that is engaging adjacent bi-stable cells 48 in the adjacent ring 52, as shown, for example, in
Adjacent bi-stable cells 48 within a ring 52 can be engaged by a connector 44. As discussed above, the connector 44 can have any configuration and length. In some embodiments, the connector 44 engaging adjacent bi-stable cells 48 in a ring 52 has a first configuration when the side branch 20 is in the unexpanded state and a second configuration when the side branch 20 is in the expanded state. Thus, if the adjacent bi-stable cells 48 are arranged so that the distance between the second segment 34 of one bi-stable cell 48 and the first segment 32 of the adjacent bi-stable cell 48 decreases upon expansion of the side branch 20, the first and second configurations of the connector 44 are different because the configuration of the connector 44 changes to accommodate the decreased distance between adjacent bi-stable cells 48.
Note that the diameter of the side branch 20 in this embodiment depends upon the number of bi-stable cells 48 in a ring 52 and the diameter of each bi-stable cell 48 in the second state 38. In some embodiments, each ring 52 has the same number of bi-stable cells 48. In some embodiments, the side branch 20 has rings 52 with different numbers of bi-stable cells 48. In one embodiment, the side branch 20 is tapered if the number of bi-stable cells 48 in the ring 52 engaged to the perimeter member 22 is greater than the end ring 52 of the side branch 20. In another embodiment, the side branch 20 is not tapered if the number of bi-stable cells 48 in the ring 52 engaged to the perimeter member 22 is less than the end ring 52 of the side branch 20. In some embodiments, the side branch 20 has at least one ring 52 that has bi-stable cells 48 and cells 49 that have only one stable state.
The following numbered statements characterize the embodiments described above:
1. A stent comprising a substantially cylindrical tubular body, the tubular body comprising at least one expandable side branch, the at least one side branch comprising:
2. The stent of statement 1, the first long member comprising a first section and a second section, the first section at an oblique angle to the second section, the first cell segment engaged to the first section of the first long member
3. The stent of statement 1, the first cell segment directly engaged to the first long member.
4. The stent of statement 3, further comprising at least one first short member, the first cell segment further engaged to the first long member by the at least one first short member.
5. The stent of statement 1, further comprising a first short member, the first cell segment indirectly engaged to the first long member by the first short member.
6. The stent of statement 1, the second cell segment having at least one hinge
7. The stent of statement 1, further comprising a perimeter member, the perimeter member defining a side branch opening, the first long member engaged to the perimeter member.
8. The stent of statement 1, the first cell segment having a first configuration in the first state, the second cell segment having a second configuration in the first state, the first and second configurations being the same.
9. The stent of statement 8, the first cell segment having the first configuration in the second state, the second cell segment having the second configuration in the second state.
10. The stent of statement 8, the first cell segment having the first configuration in the second state, the second cell segment having a third configuration in the second state, the third configuration different than the first configuration.
11. The stent of statement 1, the first cell segment having a first configuration in the first state, the second cell segment having a second configuration in the first state, the first and second configurations being the different.
12. The stent of statement 1, further comprising:
13. The stent of statement 12, the second long member having a first bend, the second end of the first connector engaged to the first bend of the second long member.
14. The stent of statement 12, further comprising:
15. The stent of statement 14, the first long member having a first end, the second long member having a first end, the first petal engaging the first ends of the first and second long members.
16. The stent of statement 14, further comprising:
17. The stent of statement 16, the second area of the second cell being less than the second area of the first cell.
18. The stent of statement 16, the third cell segment being directly engaged to the perimeter member.
19. The stent of statement 16, further comprising at least one second short member, the third cell segment being engaged to the perimeter member by at least one second short member.
20. The stent of statement 16, the fourth cell segment being engaged to the first long member.
21. The stent of statement 20, further comprising:
The inventive stents may be made from any suitable biocompatible materials including one or more polymers, one or more metals or combinations of polymer(s) and metal(s). Examples of suitable materials include biodegradable materials that are also biocompatible. By biodegradable is meant that a material will undergo breakdown or decomposition into harmless compounds as part of a normal biological process. Suitable biodegradable materials include polylactic acid, polyglycolic acid (PGA), collagen or other connective proteins or natural materials, polycaprolactone, hylauric acid, adhesive proteins, co-polymers of these materials as well as composites and combinations thereof and combinations of other biodegradable polymers. Other polymers that may be used include polyester and polycarbonate copolymers. Examples of suitable metals include, but are not limited to, stainless steel, titanium, tantalum, platinum, tungsten, magnesium, gold and alloys of any of the above-mentioned metals. Examples of suitable alloys include platinum-iridium alloys, cobalt-chromium alloys including Elgiloy and Phynox, MP35N alloy, Platinum Enhanced Radiopaque Stainless Steel (PERSS), and nickel-titanium alloys, for example, Nitinol.
The inventive stents may be made of shape memory materials such as superelastic Nitinol or spring steel, or may be made of materials which are plastically deformable. In the case of shape memory materials, the stent may be provided with a memorized shape and then deformed to a reduced diameter shape. The stent may restore itself to its memorized shape upon being heated to a transition temperature and having any restraints removed therefrom.
The inventive stents may be created by methods including cutting or etching a design from a tubular stock, from a flat sheet which is cut or etched and which is subsequently rolled or from one or more interwoven wires or braids. Any other suitable technique which is known in the art or which is subsequently developed may also be used to manufacture the inventive stents disclosed herein.
In some embodiments the stent, the delivery system or other portion of the assembly may include one or more areas, bands, coatings, members, etc. that is (are) detectable by imaging modalities such as X-Ray, MRI, ultrasound, etc. In some embodiments at least a portion of the stent and/or adjacent assembly is at least partially radiopaque.
In some embodiments the at least a portion of the stent is configured to include one or more mechanisms for the delivery of a therapeutic agent. Often the agent will be in the form of a coating or other layer (or layers) of material placed on a surface region of the stent, which is adapted to be released at the site of the stent's implantation or areas adjacent thereto.
A therapeutic agent may be a drug or other pharmaceutical product such as non-genetic agents, genetic agents, cellular material, etc. Some examples of suitable non-genetic therapeutic agents include but are not limited to: anti-thrombogenic agents such as heparin, heparin derivatives, vascular cell growth promoters, growth factor inhibitors, Paclitaxel, etc. Where an agent includes a genetic therapeutic agent, such a genetic agent may include but is not limited to: DNA, RNA and their respective derivatives and/or components; hedgehog proteins, etc. Where a therapeutic agent includes cellular material, the cellular material may include but is not limited to: cells of human origin and/or non-human origin as well as their respective components and/or derivatives thereof. Where the therapeutic agent includes a polymer agent, the polymer agent may be a polystyrene-polyisobutylene-polystyrene triblock copolymer (SIBS), polyethylene oxide, silicone rubber and/or any other suitable substrate.
The above disclosure is intended to be illustrative and not exhaustive. This description will suggest many variations and alternatives to one of ordinary skill in this art. The various elements shown in the individual figures and described above may be combined or modified for combination as desired. All these alternatives and variations are intended to be included within the scope of the claims where the term “comprising” means “including, but not limited to”.
Further, the particular features presented in the dependent claims can be combined with each other in other manners within the scope of the invention such that the invention should be recognized as also specifically directed to other embodiments having any other possible combination of the features of the dependent claims. For instance, for purposes of claim publication, any dependent claim which follows should be taken as alternatively written in a multiple dependent form from all prior claims which possess all antecedents referenced in such dependent claim if such multiple dependent format is an accepted format within the jurisdiction (e.g. each claim depending directly from claim 1 should be alternatively taken as depending from all previous claims). In jurisdictions where multiple dependent claim formats are restricted, the following dependent claims should each be also taken as alternatively written in each singly dependent claim format which creates a dependency from a prior antecedent-possessing claim other than the specific claim listed in such dependent claim below.
This completes the description of the invention. Those skilled in the art may recognize other equivalents to the specific embodiment described herein which equivalents are intended to be encompassed by the claims attached hereto.
Number | Name | Date | Kind |
---|---|---|---|
4309994 | Grunwald | Jan 1982 | A |
4769005 | Ginsburg et al. | Sep 1988 | A |
4774949 | Fogarty | Oct 1988 | A |
4896670 | Crittenden | Jan 1990 | A |
4905667 | Foerster et al. | Mar 1990 | A |
4906244 | Pinchuk et al. | Mar 1990 | A |
4935190 | Tennerstedt | Jun 1990 | A |
4994071 | MacGregor | Feb 1991 | A |
5037392 | Hillstead | Aug 1991 | A |
5053007 | Euteneuer | Oct 1991 | A |
5087246 | Smith | Feb 1992 | A |
5112900 | Buddenhagen et al. | May 1992 | A |
5147302 | Euteneuer et al. | Sep 1992 | A |
5163989 | Campbell et al. | Nov 1992 | A |
5209799 | Vigil | May 1993 | A |
5226887 | Farr et al. | Jul 1993 | A |
5306246 | Sahatjian et al. | Apr 1994 | A |
5318587 | Davey | Jun 1994 | A |
5342307 | Euteneuer et al. | Aug 1994 | A |
5342387 | Summers | Aug 1994 | A |
5348538 | Wang et al. | Sep 1994 | A |
5350361 | Tsukashima et al. | Sep 1994 | A |
5358475 | Mares et al. | Oct 1994 | A |
5387235 | Chuter | Feb 1995 | A |
5403340 | Wang et al. | Apr 1995 | A |
5447497 | Sogard et al. | Sep 1995 | A |
5456666 | Campbell et al. | Oct 1995 | A |
5456712 | Maginot | Oct 1995 | A |
5458572 | Campbell et al. | Oct 1995 | A |
5476471 | Shifrin et al. | Dec 1995 | A |
5478319 | Campbell et al. | Dec 1995 | A |
5487730 | Marcadis et al. | Jan 1996 | A |
5523092 | Hanson et al. | Jun 1996 | A |
5549552 | Peters et al. | Aug 1996 | A |
5550180 | Elsik et al. | Aug 1996 | A |
5556383 | Wang et al. | Sep 1996 | A |
5591228 | Edoga | Jan 1997 | A |
5607444 | Lam | Mar 1997 | A |
5609605 | Marshall et al. | Mar 1997 | A |
5609627 | Goicoechea et al. | Mar 1997 | A |
5613980 | Chauhan | Mar 1997 | A |
5617878 | Taheri | Apr 1997 | A |
5632762 | Myler | May 1997 | A |
5632763 | Glastra | May 1997 | A |
5632772 | Alcime et al. | May 1997 | A |
5636641 | Fariabi | Jun 1997 | A |
5669924 | Shaknovich | Sep 1997 | A |
5669932 | Fischell et al. | Sep 1997 | A |
5676697 | McDonald | Oct 1997 | A |
5683450 | Goicoechea et al. | Nov 1997 | A |
5697971 | Fischell et al. | Dec 1997 | A |
5707348 | Krogh | Jan 1998 | A |
5709713 | Evans et al. | Jan 1998 | A |
5718684 | Gupta | Feb 1998 | A |
5718724 | Goicoechea et al. | Feb 1998 | A |
5720735 | Dorros | Feb 1998 | A |
5746745 | Abele et al. | May 1998 | A |
5749825 | Fischell et al. | May 1998 | A |
5749890 | Shaknovich | May 1998 | A |
5755734 | Richter et al. | May 1998 | A |
5755735 | Richter et al. | May 1998 | A |
5755771 | Penn et al. | May 1998 | A |
5755773 | Evans et al. | May 1998 | A |
5755778 | Kleshinski | May 1998 | A |
5782906 | Marshall et al. | Jul 1998 | A |
5800520 | Fogarty et al. | Sep 1998 | A |
5810767 | Klein | Sep 1998 | A |
5824036 | Lauterjung | Oct 1998 | A |
5824040 | Cox et al. | Oct 1998 | A |
5827320 | Richter et al. | Oct 1998 | A |
5830182 | Wang et al. | Nov 1998 | A |
5833657 | Reinhardt et al. | Nov 1998 | A |
5843172 | Yan | Dec 1998 | A |
5851464 | Davila et al. | Dec 1998 | A |
5868777 | Lam | Feb 1999 | A |
5882334 | Sepetka et al. | Mar 1999 | A |
5891108 | Leone et al. | Apr 1999 | A |
5893887 | Jayaraman | Apr 1999 | A |
5906640 | Penn et al. | May 1999 | A |
5922020 | Klein et al. | Jul 1999 | A |
5922021 | Jang | Jul 1999 | A |
5951941 | Wang et al. | Sep 1999 | A |
5961548 | Shmulewitz | Oct 1999 | A |
5972017 | Berg et al. | Oct 1999 | A |
5972027 | Johnson | Oct 1999 | A |
6013054 | Jiun Yan | Jan 2000 | A |
6013055 | Bampos et al. | Jan 2000 | A |
6013091 | Ley et al. | Jan 2000 | A |
6017324 | Tu et al. | Jan 2000 | A |
6017363 | Hojeibane | Jan 2000 | A |
6030414 | Taheri | Feb 2000 | A |
6033380 | Butaric et al. | Mar 2000 | A |
6033433 | Ehr et al. | Mar 2000 | A |
6033434 | Borghi | Mar 2000 | A |
6033435 | Penn et al. | Mar 2000 | A |
6048361 | Von Oepen | Apr 2000 | A |
6056775 | Borghi et al. | May 2000 | A |
6059824 | Taheri | May 2000 | A |
6068655 | Seguin et al. | May 2000 | A |
6071285 | Lashinski et al. | Jun 2000 | A |
6071305 | Brown et al. | Jun 2000 | A |
6086611 | Duffy et al. | Jul 2000 | A |
6093203 | Uflacker | Jul 2000 | A |
6096070 | Ragheb et al. | Aug 2000 | A |
6096073 | Webster et al. | Aug 2000 | A |
6099497 | Adams et al. | Aug 2000 | A |
6113579 | Eidenschink et al. | Sep 2000 | A |
6117117 | Mauch | Sep 2000 | A |
6117156 | Richter et al. | Sep 2000 | A |
6123721 | Jang | Sep 2000 | A |
6126652 | McLeod et al. | Oct 2000 | A |
6129738 | Lashinski et al. | Oct 2000 | A |
6129754 | Kanesaka et al. | Oct 2000 | A |
6135982 | Campbell | Oct 2000 | A |
6142973 | Carleton et al. | Nov 2000 | A |
6143002 | Vietmeier | Nov 2000 | A |
6146356 | Wang et al. | Nov 2000 | A |
6159238 | Killion et al. | Dec 2000 | A |
6165195 | Wilson et al. | Dec 2000 | A |
6168621 | Vrba | Jan 2001 | B1 |
6171278 | Wang et al. | Jan 2001 | B1 |
6183509 | Dibie | Feb 2001 | B1 |
6190404 | Palmaz et al. | Feb 2001 | B1 |
6203568 | Lombardi et al. | Mar 2001 | B1 |
6206915 | Fagan et al. | Mar 2001 | B1 |
6206916 | Furst | Mar 2001 | B1 |
6210380 | Mauch | Apr 2001 | B1 |
6210429 | Vardi et al. | Apr 2001 | B1 |
6210433 | Larre | Apr 2001 | B1 |
6210436 | Weadock | Apr 2001 | B1 |
6231598 | Berry et al. | May 2001 | B1 |
6240616 | Yan | Jun 2001 | B1 |
6241762 | Shanley | Jun 2001 | B1 |
6253443 | Johnson | Jul 2001 | B1 |
6254593 | Wilson | Jul 2001 | B1 |
6254632 | Wu et al. | Jul 2001 | B1 |
6258115 | Dubrul | Jul 2001 | B1 |
6258116 | Hojeibane | Jul 2001 | B1 |
6258121 | Yang et al. | Jul 2001 | B1 |
6261305 | Marotta et al. | Jul 2001 | B1 |
6261316 | Shaolian et al. | Jul 2001 | B1 |
6261320 | Tam et al. | Jul 2001 | B1 |
6264662 | Lauterjung | Jul 2001 | B1 |
6264686 | Rieu et al. | Jul 2001 | B1 |
6273908 | Ndonda-Lay | Aug 2001 | B1 |
6273913 | Wright et al. | Aug 2001 | B1 |
6280413 | Clark et al. | Aug 2001 | B1 |
6287628 | Hossainy et al. | Sep 2001 | B1 |
6290673 | Shanley | Sep 2001 | B1 |
6293967 | Shanley | Sep 2001 | B1 |
6293968 | Taheri | Sep 2001 | B1 |
6325826 | Vardi et al. | Dec 2001 | B1 |
6328925 | Wang et al. | Dec 2001 | B1 |
6334864 | Amplatz et al. | Jan 2002 | B1 |
6334870 | Ehr et al. | Jan 2002 | B1 |
6346089 | Dibie | Feb 2002 | B1 |
6348065 | Brown et al. | Feb 2002 | B1 |
6355060 | Lenker et al. | Mar 2002 | B1 |
6358552 | Mandralis et al. | Mar 2002 | B1 |
6361544 | Wilson et al. | Mar 2002 | B1 |
6361555 | Wilson | Mar 2002 | B1 |
6379381 | Hossainy et al. | Apr 2002 | B1 |
6383213 | Wilson et al. | May 2002 | B2 |
6395018 | Castaneda | May 2002 | B1 |
6395326 | Castro et al. | May 2002 | B1 |
6406457 | Wang et al. | Jun 2002 | B1 |
6423091 | Hojeibane | Jul 2002 | B1 |
6436104 | Hojeibane | Aug 2002 | B2 |
6436134 | Richter et al. | Aug 2002 | B2 |
6478816 | Kveen et al. | Nov 2002 | B1 |
6488702 | Besselink | Dec 2002 | B1 |
6491666 | Santini, Jr. et al. | Dec 2002 | B1 |
6506437 | Harish et al. | Jan 2003 | B1 |
6508836 | Wilson et al. | Jan 2003 | B2 |
6517558 | Gittings et al. | Feb 2003 | B2 |
6520988 | Colombo et al. | Feb 2003 | B1 |
6527762 | Santini, Jr. et al. | Mar 2003 | B1 |
6527799 | Shanley | Mar 2003 | B2 |
6537256 | Santini, Jr. et al. | Mar 2003 | B2 |
6540779 | Richter et al. | Apr 2003 | B2 |
6551351 | Smith et al. | Apr 2003 | B2 |
6551838 | Santini, Jr. et al. | Apr 2003 | B2 |
6558422 | Baker et al. | May 2003 | B1 |
6562065 | Shanley | May 2003 | B1 |
6579309 | Loos et al. | Jun 2003 | B1 |
6579312 | Wilson et al. | Jun 2003 | B2 |
6582394 | Reiss et al. | Jun 2003 | B1 |
6596020 | Vardi et al. | Jul 2003 | B2 |
6599316 | Vardi et al. | Jul 2003 | B2 |
6638302 | Curcio et al. | Oct 2003 | B1 |
6645242 | Quinn | Nov 2003 | B1 |
6656162 | Santini, Jr. et al. | Dec 2003 | B2 |
6669683 | Santini, Jr. et al. | Dec 2003 | B2 |
6689156 | Davidson et al. | Feb 2004 | B1 |
6692483 | Vardi et al. | Feb 2004 | B2 |
6695877 | Brucker et al. | Feb 2004 | B2 |
6706062 | Vardi et al. | Mar 2004 | B2 |
6709379 | Brandau et al. | Mar 2004 | B1 |
6713119 | Hossainy et al. | Mar 2004 | B2 |
6730064 | Ragheb et al. | May 2004 | B2 |
6749628 | Callol et al. | Jun 2004 | B1 |
6758859 | Dang et al. | Jul 2004 | B1 |
6764507 | Shanley et al. | Jul 2004 | B2 |
6773429 | Sheppard, Jr. et al. | Aug 2004 | B2 |
6776793 | Brown et al. | Aug 2004 | B2 |
6783543 | Jang | Aug 2004 | B2 |
6790228 | Hossainy et al. | Sep 2004 | B2 |
6811566 | Penn et al. | Nov 2004 | B1 |
6827250 | Uhland et al. | Dec 2004 | B2 |
6835203 | Vardi et al. | Dec 2004 | B1 |
6858038 | Heuser | Feb 2005 | B2 |
6884258 | Vardi et al. | Apr 2005 | B2 |
6896699 | Wilson et al. | May 2005 | B2 |
6904658 | Hines | Jun 2005 | B2 |
6932837 | Amplatz et al. | Aug 2005 | B2 |
6946092 | Bertolino et al. | Sep 2005 | B1 |
6955687 | Richter et al. | Oct 2005 | B2 |
6955688 | Wilson et al. | Oct 2005 | B2 |
6962602 | Vardi et al. | Nov 2005 | B2 |
6989071 | Kocur et al. | Jan 2006 | B2 |
7018400 | Lashinski et al. | Mar 2006 | B2 |
7022131 | Derowe et al. | Apr 2006 | B1 |
7041130 | Santini, Jr. et al. | May 2006 | B2 |
7052488 | Uhland | May 2006 | B2 |
7056323 | Mareiro et al. | Jun 2006 | B2 |
7056338 | Shanley et al. | Jun 2006 | B2 |
7060084 | Loshakove et al. | Jun 2006 | B1 |
7060091 | Killion et al. | Jun 2006 | B2 |
7070616 | Majercak et al. | Jul 2006 | B2 |
7160321 | Shanley et al. | Jan 2007 | B2 |
7169175 | Cottone, Jr. et al. | Jan 2007 | B2 |
7169179 | Shanley et al. | Jan 2007 | B2 |
7179288 | Shanley | Feb 2007 | B2 |
7179289 | Shanley | Feb 2007 | B2 |
7208010 | Shanley et al. | Apr 2007 | B2 |
7208011 | Shanley et al. | Apr 2007 | B2 |
7220275 | Davidson et al. | May 2007 | B2 |
7235097 | Calisse et al. | Jun 2007 | B2 |
7722658 | Richter et al. | May 2010 | B2 |
7959668 | Yadin | Jun 2011 | B2 |
20010003161 | Vardi et al. | Jun 2001 | A1 |
20010004706 | Hojeibane | Jun 2001 | A1 |
20010004707 | Dereume et al. | Jun 2001 | A1 |
20010012927 | Mauch | Aug 2001 | A1 |
20010016766 | Vardi et al. | Aug 2001 | A1 |
20010016767 | Wilson et al. | Aug 2001 | A1 |
20010016768 | Wilson et al. | Aug 2001 | A1 |
20010025195 | Shaolian et al. | Sep 2001 | A1 |
20010027291 | Shanley | Oct 2001 | A1 |
20010027338 | Greenberg | Oct 2001 | A1 |
20010029396 | Wilson et al. | Oct 2001 | A1 |
20010037116 | Wilson et al. | Nov 2001 | A1 |
20010037138 | Wilson et al. | Nov 2001 | A1 |
20010039448 | Dibie | Nov 2001 | A1 |
20010049552 | Richter et al. | Dec 2001 | A1 |
20010056297 | Hojeibane | Dec 2001 | A1 |
20020013618 | Marotta et al. | Jan 2002 | A1 |
20020013619 | Shanley | Jan 2002 | A1 |
20020022874 | Wilson | Feb 2002 | A1 |
20020026232 | Marotta et al. | Feb 2002 | A1 |
20020035392 | Wilson | Mar 2002 | A1 |
20020038146 | Harry | Mar 2002 | A1 |
20020042650 | Vardi et al. | Apr 2002 | A1 |
20020052648 | McGuckin, Jr. et al. | May 2002 | A1 |
20020072790 | McGuckin, Jr. et al. | Jun 2002 | A1 |
20020095208 | Gregorich et al. | Jul 2002 | A1 |
20020107562 | Hart | Aug 2002 | A1 |
20020111675 | Wilson | Aug 2002 | A1 |
20020156516 | Vardi et al. | Oct 2002 | A1 |
20020156517 | Perouse | Oct 2002 | A1 |
20020163104 | Motsenbocker et al. | Nov 2002 | A1 |
20020165604 | Shanley | Nov 2002 | A1 |
20020173835 | Bourang et al. | Nov 2002 | A1 |
20020173840 | Brucker et al. | Nov 2002 | A1 |
20020183763 | Callol et al. | Dec 2002 | A1 |
20020193872 | Trout, III et al. | Dec 2002 | A1 |
20020193873 | Brucker et al. | Dec 2002 | A1 |
20030009209 | Hojeibane | Jan 2003 | A1 |
20030028233 | Vardi et al. | Feb 2003 | A1 |
20030050688 | Fischell et al. | Mar 2003 | A1 |
20030055378 | Wang et al. | Mar 2003 | A1 |
20030055483 | Gumm | Mar 2003 | A1 |
20030074047 | Richter | Apr 2003 | A1 |
20030083687 | Pallazza | May 2003 | A1 |
20030093109 | Mauch | May 2003 | A1 |
20030097169 | Brucker | May 2003 | A1 |
20030105511 | Welsh et al. | Jun 2003 | A1 |
20030114912 | Sequin et al. | Jun 2003 | A1 |
20030125791 | Sequin et al. | Jul 2003 | A1 |
20030125802 | Callol et al. | Jul 2003 | A1 |
20030135259 | Simso | Jul 2003 | A1 |
20030163157 | McMorrow et al. | Aug 2003 | A1 |
20030167085 | Shanley | Sep 2003 | A1 |
20030181923 | Vardi | Sep 2003 | A1 |
20030195606 | Davidson et al. | Oct 2003 | A1 |
20030199970 | Shanley | Oct 2003 | A1 |
20040006381 | Sequin et al. | Jan 2004 | A1 |
20040015227 | Vardi et al. | Jan 2004 | A1 |
20040044396 | Clerc et al. | Mar 2004 | A1 |
20040059406 | Cully et al. | Mar 2004 | A1 |
20040068161 | Couvillon, Jr. | Apr 2004 | A1 |
20040073294 | Diaz et al. | Apr 2004 | A1 |
20040088007 | Eidenschink | May 2004 | A1 |
20040093071 | Jang | May 2004 | A1 |
20040117003 | Ouriel et al. | Jun 2004 | A1 |
20040122505 | Shanley | Jun 2004 | A1 |
20040122506 | Shanley et al. | Jun 2004 | A1 |
20040127976 | Diaz | Jul 2004 | A1 |
20040127977 | Shanley | Jul 2004 | A1 |
20040133268 | Davidson et al. | Jul 2004 | A1 |
20040138732 | Suhr et al. | Jul 2004 | A1 |
20040138737 | Davidson et al. | Jul 2004 | A1 |
20040142014 | Livack et al. | Jul 2004 | A1 |
20040143321 | Livack et al. | Jul 2004 | A1 |
20040143322 | Livack et al. | Jul 2004 | A1 |
20040148006 | Davidson et al. | Jul 2004 | A1 |
20040148012 | Jang | Jul 2004 | A9 |
20040172121 | Eidenschink et al. | Sep 2004 | A1 |
20040186560 | Alt | Sep 2004 | A1 |
20040202692 | Shanley et al. | Oct 2004 | A1 |
20040204750 | Dinh | Oct 2004 | A1 |
20040215227 | McMorrow et al. | Oct 2004 | A1 |
20040220661 | Shanley et al. | Nov 2004 | A1 |
20040225345 | Fischell et al. | Nov 2004 | A1 |
20040236408 | Shanley | Nov 2004 | A1 |
20040249449 | Shanley et al. | Dec 2004 | A1 |
20040267352 | Davidson et al. | Dec 2004 | A1 |
20050004656 | Das | Jan 2005 | A1 |
20050010278 | Vardi et al. | Jan 2005 | A1 |
20050015108 | Williams et al. | Jan 2005 | A1 |
20050015135 | Shanley | Jan 2005 | A1 |
20050043816 | Datta et al. | Feb 2005 | A1 |
20050060027 | Khenansho et al. | Mar 2005 | A1 |
20050096726 | Sequin et al. | May 2005 | A1 |
20050102017 | Mattison | May 2005 | A1 |
20050102021 | Osborne | May 2005 | A1 |
20050102023 | Yadin et al. | May 2005 | A1 |
20050119731 | Brucker et al. | Jun 2005 | A1 |
20050125076 | Ginn | Jun 2005 | A1 |
20050131526 | Wong | Jun 2005 | A1 |
20050149161 | Eidenschink et al. | Jul 2005 | A1 |
20050154442 | Eidenschink et al. | Jul 2005 | A1 |
20050154444 | Quadri | Jul 2005 | A1 |
20050183259 | Eidenschink et al. | Aug 2005 | A1 |
20050187602 | Eidenschink | Aug 2005 | A1 |
20050187611 | Ding et al. | Aug 2005 | A1 |
20050192657 | Colen et al. | Sep 2005 | A1 |
20050209673 | Shaked | Sep 2005 | A1 |
20050222668 | Schaeffer et al. | Oct 2005 | A1 |
20050228483 | Kaplan et al. | Oct 2005 | A1 |
20050273149 | Tran et al. | Dec 2005 | A1 |
20060015134 | Trinidad | Jan 2006 | A1 |
20060034884 | Stenzel | Feb 2006 | A1 |
20060036315 | Yadin et al. | Feb 2006 | A1 |
20060041303 | Israel | Feb 2006 | A1 |
20060045901 | Weber | Mar 2006 | A1 |
20060079956 | Eigler et al. | Apr 2006 | A1 |
20060088654 | Ding et al. | Apr 2006 | A1 |
20060093643 | Stenzel | May 2006 | A1 |
20060100686 | Bolduc | May 2006 | A1 |
20060122698 | Spencer et al. | Jun 2006 | A1 |
20060155360 | Calisse et al. | Jul 2006 | A1 |
20060173528 | Feld et al. | Aug 2006 | A1 |
20060206188 | Weber et al. | Sep 2006 | A1 |
20060217795 | Besselink et al. | Sep 2006 | A1 |
20060287712 | Eidenschink | Dec 2006 | A1 |
20070005126 | Tischler | Jan 2007 | A1 |
20070050016 | Gregorich et al. | Mar 2007 | A1 |
20070073376 | Krolik et al. | Mar 2007 | A1 |
20070073384 | Brown et al. | Mar 2007 | A1 |
20070100434 | Gregorich et al. | May 2007 | A1 |
20070135904 | Eidenschink et al. | Jun 2007 | A1 |
20070173787 | Huang et al. | Jul 2007 | A1 |
20070173923 | Savage et al. | Jul 2007 | A1 |
20070208408 | Weber et al. | Sep 2007 | A1 |
Number | Date | Country |
---|---|---|
2220864 | Jul 1999 | CA |
9014845 | Feb 1991 | DE |
29701758 | Mar 1997 | DE |
29701883 | May 1997 | DE |
19921788 | Nov 2000 | DE |
0479730 | Oct 1991 | EP |
0565796 | Oct 1993 | EP |
0751752 | Jan 1997 | EP |
0783873 | Jul 1997 | EP |
0804907 | Nov 1997 | EP |
0479557 | Jul 1998 | EP |
0876805 | Nov 1998 | EP |
0880949 | Dec 1998 | EP |
0891751 | Jan 1999 | EP |
0895759 | Feb 1999 | EP |
0904745 | Mar 1999 | EP |
0937442 | Aug 1999 | EP |
0950386 | Oct 1999 | EP |
0347023 | Dec 1999 | EP |
1031328 | Aug 2000 | EP |
1031329 | Aug 2000 | EP |
0883384 | Dec 2000 | EP |
0862392 | Aug 2001 | EP |
0808140 | Dec 2001 | EP |
0884028 | Feb 2002 | EP |
1190685 | Mar 2002 | EP |
0897700 | Jul 2002 | EP |
0684022 | Feb 2004 | EP |
1157674 | Jul 2005 | EP |
1031330 | Nov 2005 | EP |
1070513 | Jun 2006 | EP |
2678508 | Jan 1993 | FR |
2740346 | Oct 1995 | FR |
2756173 | Nov 1996 | FR |
2337002 | May 1998 | GB |
8806026 | Aug 1988 | WO |
9423787 | Oct 1994 | WO |
9521592 | Aug 1995 | WO |
9629955 | Oct 1996 | WO |
9634580 | Nov 1996 | WO |
9641592 | Dec 1996 | WO |
9707752 | Mar 1997 | WO |
9715346 | May 1997 | WO |
9716217 | May 1997 | WO |
9726936 | Jul 1997 | WO |
9741803 | Nov 1997 | WO |
9745073 | Dec 1997 | WO |
9746174 | Dec 1997 | WO |
9819628 | May 1998 | WO |
9823228 | Jun 1998 | WO |
9832412 | Jul 1998 | WO |
9836709 | Aug 1998 | WO |
9836784 | Aug 1998 | WO |
9837833 | Sep 1998 | WO |
9847447 | Oct 1998 | WO |
9848879 | Nov 1998 | WO |
9903426 | Jan 1999 | WO |
9904726 | Feb 1999 | WO |
9915103 | Apr 1999 | WO |
9915108 | Apr 1999 | WO |
9915109 | Apr 1999 | WO |
9923977 | May 1999 | WO |
9924104 | May 1999 | WO |
9929262 | Jun 1999 | WO |
9934749 | Jul 1999 | WO |
9936002 | Jul 1999 | WO |
9936015 | Jul 1999 | WO |
9944539 | Sep 1999 | WO |
9956661 | Nov 1999 | WO |
9965419 | Dec 1999 | WO |
0007523 | Feb 2000 | WO |
0010489 | Mar 2000 | WO |
0016719 | Mar 2000 | WO |
0027307 | May 2000 | WO |
0027463 | May 2000 | WO |
0028922 | May 2000 | WO |
0145594 | Jun 2000 | WO |
0044307 | Aug 2000 | WO |
0044309 | Aug 2000 | WO |
0047134 | Aug 2000 | WO |
0048531 | Aug 2000 | WO |
0049951 | Aug 2000 | WO |
0051523 | Sep 2000 | WO |
0057813 | Oct 2000 | WO |
0067673 | Nov 2000 | WO |
0071054 | Nov 2000 | WO |
0071055 | Nov 2000 | WO |
0074595 | Dec 2000 | WO |
0117577 | Mar 2001 | WO |
0121095 | Mar 2001 | WO |
0121109 | Mar 2001 | WO |
0121244 | Mar 2001 | WO |
0126584 | Apr 2001 | WO |
0135715 | May 2001 | WO |
0135863 | May 2001 | WO |
0139697 | Jun 2001 | WO |
0139699 | Jun 2001 | WO |
0141677 | Jun 2001 | WO |
0143665 | Jun 2001 | WO |
0143809 | Jun 2001 | WO |
0145785 | Jun 2001 | WO |
0149342 | Jul 2001 | WO |
0154621 | Aug 2001 | WO |
0154622 | Aug 2001 | WO |
0158385 | Aug 2001 | WO |
0160284 | Aug 2001 | WO |
0166036 | Sep 2001 | WO |
0170294 | Sep 2001 | WO |
0170299 | Sep 2001 | WO |
0174273 | Oct 2001 | WO |
0191918 | Dec 2001 | WO |
0193781 | Dec 2001 | WO |
0200138 | Jan 2002 | WO |
02053066 | Jul 2002 | WO |
02068012 | Sep 2002 | WO |
03007842 | Jan 2003 | WO |
03055414 | Jul 2003 | WO |
03063924 | Aug 2003 | WO |
2004026174 | Apr 2004 | WO |
2004026180 | Apr 2004 | WO |
2005009295 | Feb 2005 | WO |
2005014077 | Feb 2005 | WO |
2005041810 | May 2005 | WO |
2005122959 | Dec 2005 | WO |
2006028925 | Mar 2006 | WO |
2006074476 | Jul 2006 | WO |
2006127127 | Nov 2006 | WO |
Number | Date | Country | |
---|---|---|---|
20090163993 A1 | Jun 2009 | US |